Significantly, administration of HMGB1 inhibitors or antibodies specific for HMGB1 improves inflammation-related disorders such as sepsis, colitis, and ischemic reperfusion (Wang et al., 1999; Davé et al., 2009; Andrassy et al., 2008). The gene discussed is HMGB1; the disease is colitis.